<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840280</url>
  </required_header>
  <id_info>
    <org_study_id>ONKOIRI01</org_study_id>
    <nct_id>NCT01840280</nct_id>
  </id_info>
  <brief_title>A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer</brief_title>
  <official_title>Open, Multicenter Observational Study of Irinotecan Utilized in Mono- or Combination Therapy for the Treatment of Advanced Colorectal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onkovis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AKP Freiburg GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Onkovis GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this observational study with Irinotecan onkovis is to determine the
      number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose
      under the special circumstances of ambulant chemotherapy.

      Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This
      includes provision of appropriate packaging sizes to decrease the excess quantity to be
      discarded, and thus also follows this objective.

      Secondary objective is the assessment of the side effects of Irinotecan onkovis. To this end,
      data regarding co-medication and adverse events are also collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Quantity of Irinotecan onkovis needed per treatment cycle</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Determine the quantity of Irinotecan onkovis needed pro treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events during and after treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>The number and kind of adverse events during and after the intra-venous application of Irinotecan will be assessed and documented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">324</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carcinoma, Irinotecan onkovis (Irinotecan)</arm_group_label>
    <description>Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in practices, clinics, hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for Irinotecan according to the SmPC and treating physician

        Exclusion Criteria:

          -  according to the Irinotecan SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Elstra</city>
        <zip>01920</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Leipzig</city>
        <zip>04179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Neustadt/Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Werdau</city>
        <zip>08412</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>ambulant chemotherapy</keyword>
  <keyword>treatment cycles</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Irinotecan onkovis</keyword>
  <keyword>Quantity of Irinotecan</keyword>
  <keyword>Packaging Sizes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

